1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

SCAI, Manufacturers Defend Peripheral Paclitaxel Devices Against Doubts

 
• By Reed Miller

The Society for Cardiovascular Angiography and Interventions’ Vascular Disease Council says the recent meta-analysis finding a higher long-term mortality risk with paclitaxel-eluting peripheral devices can only be viewed as hypothesis-generating. The long-term risks of these devices should be investigated with patient-level data, SCAI argues. Several clinical data presentations at the recent LINC meeting in Leipzig showed comparable mortality rates with paclitaxel-eluting devices as comparable non-drug-eluting devices.

MT1901_Atherosclerosis_692176708_1200.jpg
• Source: shutterstock.com

A recent meta-analysis calling into question the safety of paclitaxel-coated balloons and paclitaxel-eluting stents was appropriately conducted within the constraints of trial-level data but the conclusions should only be viewed as hypothesis-generating, says the Society for Cardiovascular Angiography and Interventions (SCAI) Vascular Disease Council.

On Dec. 6, the Journal of the American Heart Association published a meta-analysis of 28 randomized trials with a total...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Clinical Trials

Breast Tissue Regeneration: Tensive’s Journey To Restore ‘Wholeness’ For Cancer Survivors

 
• By Natasha Barrow

Medtech Insight spoke with Sanjay Kakkar, Tensive CEO, about the firm’s breast tissue regeneration implant and its surgical benefits, including a reduced operation time of 74 minutes. He anticipates regulatory approval for Regenera in early 2027.

Mendaera’s Handheld Robotic System Poised To ‘Transform Needle-Based Procedures’ Starting In Urology

 
• By Marion Webb

After receiving US FDA clearance and reporting first successful use at Mayo Clinic, the Silicon Valley start-up plans to partner with leading centers to transform needle-based procedures with its robotic system starting with urology, then expand into other specialties, the CEO said.

Asabys Partners Talks SafeHeal €10M Investment At LSI Europe

 
• By Natasha Barrow

SafeHeal has secured an additional €10m for its Colovac device, bringing its total funding to €97.5m. Led by Asabys Partners, this funding offers both economic and clinical benefits, potentially reducing costs and complications associated with temporary stomas.

Brazil Asks Stakeholders To Weigh In On Ways To Improve Country’s Trial Environment

 
• By Francesca Bruce

Brazil is planning to update its National Clinical Research Action Plan to make the country a more competitive location to conduct R&D.

More from R&D

Brazil Asks Stakeholders To Weigh In On Ways To Improve Country’s Trial Environment

 
• By Francesca Bruce

Brazil is planning to update its National Clinical Research Action Plan to make the country a more competitive location to conduct R&D.

PathAI Expands AISight Dx Label With PCCP-Guided Addition Of Roche Scanners

 
• By Natasha Barrow

Roche’s scanners have been integrated with PathAI’s AISight Dx system. The system’s FDA-cleared PCCP allows new components to be validated and integrated without additional FDA clearance. Eric Walk, chief medical officer, hints at future biopharma companion diagnostic collaborations.

Salient Bio Raises £2.35M For March 2026 Rollout Of At-Home IBD Microbiome Test

 
• By Natasha Barrow

Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.